Evidence map›Paper›PMID 39359734›Full record

ArticleFrontiers in immunology2024

Paula Uittenbogaard, Stejara A Netea, Michael W T Tanck, Judy Geissler, Piotr Buda, Monika Kowalczyk-Domagała, Magdalena Okarska-Napierała, Diana van Stijn, Carline E Tacke, US Kawasaki Disease Genetics Consortium and 6 more

Abstract read
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Association ofFrontiers in immunology · 2025
    Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Paula Uittenbogaard *Department of Blood Cell Research, Sanquin Research Institute, University of Amsterdam (UvA), Amsterdam, Netherlands.
Stejara A Netea *Department of Pediatric Immunology, Rheumatology and Infectious Diseases, Emma Children's Hospital, Amsterdam University Medical Center (Amsterdam UMC), UvA, Amsterdam, Netherlands.
Michael W T TanckDepartment of Epidemiology and Data Science, Amsterdam UMC, Location UvA, Amsterdam, Netherlands.
Judy GeisslerDepartment of Blood Cell Research, Sanquin Research Institute, University of Amsterdam (UvA), Amsterdam, Netherlands.
Piotr BudaDepartment of Pediatrics, Nutrition and Metabolic Diseases, The Children's Memorial Health Institute, Warsaw, Poland.
Monika Kowalczyk-DomagałaDepartment of Pediatric Cardiology, The Children's Memorial Health Institute, Warsaw, Poland.
Magdalena Okarska-NapierałaDepartment of Pediatrics with Clinical Assessment Unit, Medical University of Warsaw, Warsaw, Poland.
Diana van StijnDepartment of Pediatric Immunology, Rheumatology and Infectious Diseases, Emma Children's Hospital, Amsterdam University Medical Center (Amsterdam UMC), UvA, Amsterdam, Netherlands.
Carline E TackeDepartment of Pediatric Immunology, Rheumatology and Infectious Diseases, Emma Children's Hospital, Amsterdam University Medical Center (Amsterdam UMC), UvA, Amsterdam, Netherlands.
US Kawasaki Disease Genetics Consortium
David P BurgnerMurdoch Children's Research Institute, Royal Children's Hospital, Melbourne, VIC, Australia.
Chisato ShimizuDepartment of Pediatrics, University of California, San Diego, La Jolla, CA, United States.
Jane C BurnsDepartment of Pediatrics, University of California, San Diego, La Jolla, CA, United States.
Irene M KuipersDepartment of Pediatric Cardiology, Amsterdam UMC, UvA, Amsterdam, Netherlands.
Taco W Kuijpers *Department of Blood Cell Research, Sanquin Research Institute, University of Amsterdam (UvA), Amsterdam, Netherlands.
Sietse Q Nagelkerke *Department of Blood Cell Research, Sanquin Research Institute, University of Amsterdam (UvA), Amsterdam, Netherlands.

Funding

Innate Immune Activation and Endothelial Cell Dysfunction in Acute Kawasaki DiseaseR01HL140898 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BURNS, JANE C, HOFFMAN, HAROLD M · 2018 to 2022
$4.3M
NHLBI NIH HHS R01 HL140898
6 · The paper itself

Abstract

Introduction: Kawasaki disease (KD) is a pediatric vasculitis that can result in coronary artery aneurysm (CAA) formation, which is a dangerous complication. Treatment with intravenous immunoglobulin (IVIg) significantly decreases the risk of CAA, possibly through competitive binding to Fc-gamma receptors (Fc Materials and methods: We investigated the association of single-nucleotide polymorphisms (SNPs) and copy number variations (CNVs) at the Results: Discussion:

Indexed as

Coronary AneurysmGenetic Predisposition to DiseaseImmunoglobulins, IntravenousMucocutaneous Lymph Node SyndromePolymorphism, Single NucleotideReceptors, IgGCase-Control StudiesChildChild, PreschoolDNA Copy Number VariationsDrug ResistanceFemaleHumansInfantMaleFCGR2A protein, humanFCGR3A protein, humanImmunoglobulins, IntravenousReceptors, IgGCAAFCGR2FCGR2Ap.His166ArgFCGR3geneticsIVIgKawasaki disease

Identifiers

PMID39359734
PMCPMC11445592

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.